Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV adrenal gland carcinoma that is unlikely to respond to existing therapy and for which no curative therapy exists~* Measurable disease by MRI or CT scan~* Tumor must be greater than 2 cm at the largest diameter for the lymph nodes located in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in the largest diameter for other localizations~PATIENT CHARACTERISTICS:~Age:~* 6 months and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections or fever~* No other concurrent serious disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from any prior operative procedure~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agent allowed

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).